The State Council's major documents may affect all pharmaceutical companies

Pharma Network February 4 - Recently, the General Office of the Cpc Central Committee and the General Office of the State Council issued the Action Plan for Building a High Standard Market System.
The Action Plan, starting from the links and areas that restrict the development of the market system most prominently, the most urgent response of the masses, the most concern of all sectors of society, and the weakest market supervision, puts forward for the first time "through the efforts of about 5 years, the basic construction of a unified and open, orderly competition, complete system, perfect governance of the high standard market system", around the basic system, factor market, environmental quality, market opening, market supervision and other five aspects put forward 51 specific measures to promote action to achieve results.
, a number of content related to the pharmaceutical industry, as follows: strengthen the protection of intellectual property rights.
to promote the implementation of the provisions of the law applicable to the trial of civil cases of infringement of trade secrets, the introduction of the trial of drug-related market review and approval of patent civil cases applicable to a number of issues of the law.
to study and formulate rules for the protection of intellectual property rights in the field of drug patent protection and cross-border e-commerce, and to prepare and publish guidelines for the protection of intellectual property rights of enterprises and national guidelines for the protection of intellectual property rights.
strengthen and improve anti-monopoly and anti-unfair competition enforcement.
firmly oppose monopoly and unfair competition.
to formulate anti-monopoly guidelines in special areas such as raw materials and pharmaceuticals, and to apply the exemption system, and issue guidelines for the implementation of anti-monopoly compliance outside the enterprise.
to improve the platform enterprise monopoly identification, data collection and use management, consumer rights and interests protection and other aspects of the legal norms.
strengthen anti-monopoly and anti-unfair competition regulations in new industries such as platform economy and sharing economy.
improve the list system of fees and charges of enterprises, and severely investigate and punish the illegal charging behavior of enterprises.
promote the supervision of credit classification classification.
To promote tax administration, import and export, ecological environmental protection, medical security, pharmaceutical recruitment and other key areas in-depth implementation of credit classification supervision, according to the credit status of regulatory objects to take differentiated regulatory measures to provide market subjects with more accurate and convenient services.
guide the healthy development of platform enterprises.
support the platform for enterprises to innovate and develop and enhance international competitiveness.
Implement network infrastructure transformation and upgrading projects such as education, medical care, express logistics, promote the development of new service platforms such as Internet medical care, online education, third-party logistics, instant delivery, online office, online work, and effectively play the role of platform enterprises in the optimization and integration of factor configuration.
smooth market data flow, integrate online and offline payment transaction data, promote cross-sectoral sharing.
develop the platform economy in accordance with the law and strengthen the supervision of the platform enterprises.
the opening up of the social service market in an orderly manner.
focus on medical care, education, sports, child care, environmental protection, municipal and other fields, reduce market access restrictions, remove unreasonable restrictions on for-profit medical care, education and other institutions in the processing of certification, equipment acquisition and so on.
improve the way medical institutions are planned, implement guiding plans for social-run medical institutions, and strengthen the services of social capital investment in medical institutions.
from the above points of view, including strengthening the protection of drug patents, strengthening anti-monopoly of raw materials, the implementation of credit supervision of pharmaceutical recruitment, and promoting the development of Internet medical care are all very important measures to promote the development of the pharmaceutical industry.
well known that there can be no pharmaceutical innovation without intellectual property protection, and the protection of intellectual property rights in China plays a very important role in encouraging pharmaceutical innovation.
the Fourth Amendment to the Patent Law in October 2020 and will come into effect on June 1, 2021.
it is learned that the new Patent Law has added an early settlement mechanism for drug patent disputes in the protection of intellectual property rights of innovative drugs, and for the first time proposed a compensation system for the duration of patent rights of new drugs at the legislative level.
this time, the country re-issued a paper focusing on the protection of drug patents, I believe that the future system and mechanism for drug patent protection will be constantly improved to further promote the development of china's new drug research and development innovation.
monopoly of raw materials is also the focus of the state market regulatory authorities in recent years to combat the behavior.
, the price of preparations has soared, gone out of stock and been out of stock due to monopoly price increases.
provinces have issued notices of shortages of medicines due to rising prices for raw materials, which have prevented supplies from being guaranteed.
, the State Administration of Markets has issued huge fines to a number of pharmaceutical companies suspected of monopolizing raw materials.
addition, the policy level of anti-monopoly of RAW drugs has also been continuously improved.
Following the 2017 National Development and Reform Commission's Guidelines on Price Behavior of Operators of Shortaged Medicines and API, on October 13, 2020, the State Administration of Market Supervision and Administration issued the Antitrust Guidelines on RAW Drugs (Draft for Comments).
The Guide defines and stipulates in great detail the illegal acts of monopoly in the field of API, with the aim of promoting the healthy development of the API industry, maintaining the order of market competition in the API field, protecting the interests of consumers and the public interest, and preventing and suppressing monopoly in the field of API.
With the introduction of the Action Plan for Building a High Standard Market System, the pharmaceutical industry, with innovation as the core driving force, will also usher in a new stage of development, which will promote the healthy development of the capital market and develop the market for knowledge, technology and data factors.